Skip to main content
PMC home page
Acta Pharmaceutica Sinica. B logoLink to Acta Pharmaceutica Sinica. B
. 2023 Aug 7;13(11):4664–4666. doi: 10.1016/j.apsb.2023.08.007

Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]

Canhao Wu a,b,†, Qin Xu a,†, Huiyuan Wang b,∗, Bin Tu b,c, Jiaxin Zeng a,b, Pengfei Zhao b,d, Mingjie Shi b, Hong Qiu b,∗, Yongzhuo Huang b,c,e,f,∗
PMCID: PMC10638520  PMID: 37969729

The authors regret in the initially published version of this article, there is a misapplied image in Fig. 3C. The corrected Fig. 3 is provided below.

The authors would like to apologize for any inconvenience caused.

The original Fig. 3 was:

Image 1

Open in a new tab

Fig. 3 is revised as:

Image 2

Open in a new tab

Footnotes

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

Contributor Information

Huiyuan Wang, Email: wanghuiyuan@simm.ac.cn.

Hong Qiu, Email: hongqiu@simm.ac.cn.

Yongzhuo Huang, Email: yzhuang@simm.ac.cn.

Articles from Acta Pharmaceutica Sinica. B are provided here courtesy of Elsevier

RESOURCES